CARLSBAD, Calif., March 21, 2018 /PRNewswire/ -- GIMDx, Inc. ("GIMDx") a US subsidiary of Guangzhou Improve Medical InstrumentsCo., Ltd., announces accelerated commercialization of IncellDx, Inc.'s ("IncellDx") HPV E6/E7 OncoTect mRNA in situ Hybridization Detection Kit at its sister subsidiary, Improve Labs. The acceleration is facilitated by the recent publication
Improve Labs in Guangzhou, China, is a specialty cancer diagnostics laboratory officially licensed by the Chinese government (similar to a US CLIA laboratory) and is actively working with Tier 3 hospitals in Guangdong Province and greater China. The publication of this patent is expected to decrease the time required for the test to receive regulatory approval in China.
Dr. Larry Liu, President and CEO of GIMDx states, " to serve the rapidly growing Chinese cancer diagnostics market, Improve Medical will continue to introduce US sourced, innovative and advanced molecular diagnostic tests like IncellDx's HPV OncoTect based on the application of next generation flow cytometry platforms."
Dr. Bruce Patterson, CEO and founder of IncellDx said, "we are excited about these key additions to our extensive IP portfolio especially in the HPV/cervical cancer space. We are even more excited that these patents will accelerate Improve Medical's commercial efforts for our collaboration in the Chinese IVD markets."
About GIMDx, Inc.
GIMDx specializes in commercial collaborations and R&D laboratory support for IVD companies with particular emphasis on addressing China's unique market needs by leveraging our parent company's established commercial channels in leading Chinese hospitals, as well as other partners in the Chinese healthcare market.
For more information please see: www.gimdx.com
About IncellDx, Inc.
IncellDx, Inc., located at Menlo Park, California, USA is a single cell diagnostic company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables quantitative, simultaneous cell classification and single cell protein analysis, multiplex RNA in situ hybridization, and DNA cell cycle analysis.
View original content:http://www.prnewswire.com/news-releases/gimdx-inc-and-incelldx-inc-announce-acceleration-of-chinese-commercialization-of-hpv-oncotect-kit-300617046.html
SOURCE GIMDx, Inc.
Subscribe to our Free Newsletters!